Type I interferons in inflammatory and infectious disease

dc.contributor.advisorChairperson, Graduate Committee: Mark Jutilaen
dc.contributor.authorSnyder, Deann Teresaen
dc.contributor.otherAmanda Robison, Sharon Kemoli, Emily Kimmel, Jeff Holderness, Mark A. Jutila and Jodi F. Hedges were co-authors of the article, 'Oral delivery of oligomeric procyanidins in Applepoly® enhances type I interferon response in vivo' in the journal 'Journal of leukocyte biology' which is contained within this thesis.en
dc.contributor.otherJodi F. Hedges, Amanda Robison, Susan C. Broadaway, Seth T. Walk and Mark A. Jutila were co-authors of the article, 'Type I IFN dependent and independent host responses during clostridium difficile infection' submitted to the journal 'Infection and immunity' which is contained within this thesis.en
dc.date.accessioned2016-10-23T21:27:10Z
dc.date.available2016-10-23T21:27:10Z
dc.date.issued2016en
dc.description.abstractType I interferons were discovered based on their capacity to induce a potent antiviral response in the face of viral challenge. They are now known to induce a variety of outcomes, which greatly depend on immune context. Immune context is shaped by viral, bacterial, autoimmune or other immune-altering scenarios. The role of type I interferons varies greatly from being beneficial to the host in some infectious contexts and detrimental in others. Additionally, type I interferons are currently used as treatments for some conditions including infection with hepatitis C virus and the autoimmune condition, multiple sclerosis (MS). These treatments however, come with a host of side effects and problematic outcomes including production of antibodies that neutralize type I interferons. There is a clear need for better understanding of the roles of type I interferons in various disease settings and for treatments that can complement or negate the use of type I interferons as treatments so as to avoid undesirable consequences of treatment. An exciting new area of therapeutic investigation is researching natural compounds like oligomeric procyanidins which we have shown to have immunomodulatory and type I interferon-related effects. Through the use of in vitro experiments with human peripheral blood mononuclear cells and in vivo experiments with murine models, we demonstrated a role for type I interferon signaling in the emerging disease, Clostridium difficile infection, and propose the use of oligomeric procyanidins derived from apple polyphenols as a potential treatment.en
dc.identifier.urihttps://scholarworks.montana.edu/handle/1/9859en
dc.language.isoenen
dc.publisherMontana State University - Bozeman, College of Letters & Scienceen
dc.rights.holderCopyright 2016 by Deann Teresa Snyderen
dc.subject.lcshInterferonen
dc.subject.lcshClostridium difficileen
dc.titleType I interferons in inflammatory and infectious diseaseen
dc.typeThesisen
mus.data.thumbpage66en
thesis.catalog.ckey3149357en
thesis.degree.committeemembersMembers, Graduate Committee: Seth Walk; Jodi Hedgesen
thesis.degree.departmentMicrobiology & Immunology.en
thesis.degree.genreThesisen
thesis.degree.nameMSen
thesis.format.extentfirstpage1en
thesis.format.extentlastpage91en

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
SnyderD0516.pdf
Size:
1.55 MB
Format:
Adobe Portable Document Format
Copyright (c) 2002-2022, LYRASIS. All rights reserved.